{"entity":{"id":"barbara-eichhorst","kind":"person","name":"Barbara Eichhorst","aka":[],"tldr":"Led CLL13 (GAIA), showing venetoclax-based fixed-duration therapy beats chemoimmunotherapy in fit CLL patients.","summary":"Barbara Eichhorst was principal investigator of CLL13/GAIA, the trial showing venetoclax plus obinutuzumab, with or without ibrutinib, achieves higher MRD-negativity and longer progression-free survival than FCR or BR in fit patients with untreated CLL, extending fixed-duration therapy to the fit population. She led CLL10 (FCR versus BR) and chairs the ESMO CLL guidelines.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eichhorst%20B%5BAuthor%5D%20chronic%20lymphocytic%20leukemia"}],"tags":["cll","venetoclax","guidelines"],"related":[],"cancers":["cll"],"sections":[],"technologies":["mrd-testing"],"targets":["bcl2","cd20"],"drugs":["venetoclax"],"companies":[],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":["cll13-gaia"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Head of the CLL Outpatient Clinic, University Hospital Cologne; Secretary, German CLL Study Group","institutionId":"uniklinik-koeln","specialisms":["Chronic lymphocytic leukaemia","Time-limited combinations","Chemoimmunotherapy","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eichhorst%20B%5BAuthor%5D%20chronic%20lymphocytic%20leukemia"}],"papers":[{"title":"First-line venetoclax combinations in chronic lymphocytic leukemia (CLL13/GAIA)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2213093"},{"title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10)","journal":"Lancet Oncology","year":2016,"doi":"10.1016/S1470-2045(16)30051-1"}]},"route":"/people/barbara-eichhorst/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"drug":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"institution":[{"id":"uniklinik-koeln","kind":"institution","name":"Uniklinik Köln (CIO)","route":"/institutions/uniklinik-koeln/"}],"trial":[{"id":"cll13-gaia","kind":"trial","name":"CLL13 / GAIA","route":"/trials/cll13-gaia/"}]}}